Identifying risk factors for development of nephrolithiasis in end-stage renal disease patients

Charles Hesswani, MD1; Sameena Iqbal, MD2; Khashayar Rafat Zand, MD3; Simon Sun, MD3; Bernard Unikowsky, MD2; Caroline Reinhold, MD3; Sero Andonian, MD1

1Department of Urology, McGill University, Montreal, QC, Canada; 2Department of Nephrology, McGill University, Montreal, QC, Canada; 3Department of Radiology, McGill University, Montreal, QC, Canada

Cite as: Can Urol Assoc J 2020;14(5):E185-90. http://dx.doi.org/10.5489/cuaj.6017

Published online November 29, 2019

Abstract

Introduction: We sought to assess the incidence and risk factors for stone development in patients with end-stage renal disease (ESRD) on hemodialysis (HD).

Methods: Medical records of patients receiving HD between 2007 and 2017 were retrospectively reviewed. Patients who had been on HD for at least three months and had imaging studies (computed tomography [CT] scans or ultrasound [US]) pre- and post-initiation of HD were included. Exclusion criterion was presence of stones pre-HD. De novo stones were defined as renal stones found on followup imaging. Demographics, laboratory data, comorbidities, and dialysis characteristics were compared between non-stone-formers and stone-formers using propensity score matching.

Results: A total of 133 patients met the inclusion criteria. Their median age was 68.5 years, median body mass index 28.7 kg/m², and median dialysis duration 59.5 months. After HD, 14 (10.5%) patients developed de novo stones and their median dialysis-to-stone duration was 23.5 months. When compared with non-stone-formers, stone-formers had significantly lower incidence of hypertension (48.2% vs. 14.3%; p=0.03), lower serum ionized calcium (1.16 vs. 1.07 mmol/L; p=0.01) and magnesium (0.95 vs. 0.81 mmol/L; p=0.01), and significantly higher serum uric acid (281.5 vs. 319.0 µmol/L; p=0.03). Multivariate analysis demonstrated that lower serum ionized calcium (adjusted odds ratio [OR] 0.00001; 95% confidence interval [CI] 0–0.18) and magnesium (adjusted OR 0.0003; 95% CI 0–0.59) were significantly associated with stone-formation.

Conclusions: The incidence of de novo nephrolithiasis in ESRD patients on HD was 10.5%. Increased serum uric acid, decreased serum magnesium and ionized calcium, and absence of hypertension were associated with increased stone-formation in ESRD patients on HD.

Introduction

Nephrolithiasis is an increasingly prevalent disease and is a major cause of morbidity in the working-age population.1 Its estimated prevalence is 10.6% in men and 7.1% in women.1 Risk factors for nephrolithiasis in the general population include dehydration, hypercalciuria, hypernatremia, hyperuricosuria, hyperoxaluria, hypocalcemia, and hypomagnesemia.2,3 While incidence and risk factors for nephrolithiasis are well-studied in patients with normal renal function, there is paucity of literature regarding the incidence and risk factors for de novo nephrolithiasis in patients with end-stage renal disease (ESRD) on hemodialysis (HD). It is a common belief that patients with ESRD do not form renal stones due to their oliguric or anuric state (expert opinion).4 However, two studies have shown that the incidence of de novo nephrolithiasis in patients on chronic HD is 5–13%, similar to non-ESRD population.1,5 Unfortunately, nephrolithiasis is underdiagnosed in ESRD patients presenting with renal colic.4 Stone-formation and composition in patients with ESRD are thought to be different than those formed in non-ESRD patients.6,7 Therefore, stone development in patients with ESRD on HD may be associated with risk factors different than those involved in stone-formation in non-ESRD patients.8,9 However, there is no literature regarding risk factors for de novo nephrolithiasis in this population. The aim of the present study was to assess the incidence and risk factors for de novo nephrolithiasis in patients with ESRD on HD.

Methods

After obtaining institutional ethics board approval, electronic records of all patients with ESRD undergoing HD between 2007 and 2017 at two tertiary care centers were reviewed. Data collected included: age at the start of dialysis, sex, body mass index (BMI), history of nephrolithiasis, dialysis duration, cystic kidney disease, hypertension, diabetes mellitus (DM), gout, sleep apnea, and history of bowel resection. The dialysis duration was defined from the initiation of dialysis until the last imaging study performed while actively on dialysis. Past medical and surgical history and list of medications were recorded. Serum studies included electrolytes, parathyroid hormone levels, hematocrit, glycated hemoglobin, uric acid, calcium, creatinine, and calcium. The blood work was drawn in the first
week of the month the subject was diagnosed with the renal stone. They were drawn at the initiation of the hemodialysis treatment. No stone analyses were performed and only two patients had 24-hour urine collections; therefore, no statistical analysis were obtained for these variables.

Inclusion criteria were ESRD, chronic HD for at least three months, available imaging studies (ultrasound [US] or computed tomography [CT] scans) at a minimum one year before and at least three months after HD. Patients on peritoneal dialysis were excluded, given the paucity of data regarding stone-formation in this population, as well as a potentially different mechanisms for stone-formation when compared to patients on HD. Exclusion criteria were acute HD (less than three months and results in renal recovery), known nephrolithiasis antedating HD, and inadequate imaging, defined as lack of imaging prior to and/or post-HD. The same imaging modalities were compared pre- and post-HD (i.e., US and CT scans were not compared to each other). All CT images were reviewed by two radiologists. If there was a discrepancy between the two radiologists, a third radiologist read the CT images. Given that US imaging is highly technician-dependent, images were not reviewed. However, all US examinations were performed by a select cohort of centralized radiologists within the same institution. Consensus was achieved for CT scans in all cases. Data collected were presence of nephrolithiasis (>3 mm), Randall’s plaques (<3 mm), and vascular calcifications, in addition to size (mm) and stone density on CT scans (Hounsfield units [HU]). For each stone, stone densities in HU were measured using both the largest oval-shape tool and free-hand region-of-interest tool to avoid the grey pixels in the soft-tissue window (W/L=350/40).

Mean, median, and standard deviation (SD) of stone densities were calculated. For US, the presence or absence of stones in the radiology report was recorded. Acoustic shadowing, twinkle artifact, and size >3 mm were generally used to diagnose stones on ultrasound. De novo stones were defined as symptomatic or asymptomatic renal stones found on imaging after at least three months of HD, with prior imaging that is negative for nephrolithiasis.

Statistical analysis

Descriptive data were summarized using proportions, means with SD, and medians with ranges as appropriate. Student t, Kruskal-Wallis, and Fisher’s exact tests were used to compare categorical and continuous variables between stone-former and non-stone-former ESRD HD patients. Propensity score-matching was calculated using a binary logistic regression analysis to match stone-formers and non-stone-formers based on age, gender, comorbidities and duration of dialysis. Stone-formers and non-stone-formers were matched in a 1:4 ratio, respectively. A multivariate model was generated using variables that had p-value less than 0.25 on univariate analyses, applying Poisson regression. All data analysis was performed using SAS 9.4® software (Cary, NC: SAS Institute Inc.). A two-sided level of significance <0.05 was considered significant.

Results

Out of 993 patients reviewed, 133 patients met the inclusion criteria and were included in the study (Fig. 1). The median age was 67.5 (range 26–89) years and the median BMI was 28.7 (range16–52) kg/m2. Females comprised 48.6% of patients. The median HD duration was 59.5 (range 7–201) months.
Comorbidities present included hypertension in 41.4%, DM in 52.9%, gout in 4.3%, obstructive sleep apnea in 18.6%, and previous bowel resection in 12.9% (Table 1). The etiology for the development of ESRD was multifactorial in 44 (33.1%) patients, diabetes in 20 (15.3%) patients, hypertension in 31 (22.7%) patients, polycystic kidney disease in 10 (7.4%) patients, autoimmune disease in 10 (7.4%) patients, neoplasm in five (3.1%) patients, syndromic/congenital in two (1.5%) patients, and unknown in eight (6.3%) patients (Fig. 1).

Fourteen patients (10.5%) (1.99 patients per 1000 person-months on HD) developed de novo nephrolithiasis (11 on CT scans and 3 on US imaging), with median dialysis-to-stone duration of 23.5 (range 7–99) months (Fig. 1, Table 1). None of these 14 imaging tests were performed in order to diagnose renal stones. Median stone size and density on CT were 4.2 mm (range 2.7–12.0) and 260.7 HU (range 140.7–555.3) (Table 1). The time from pre-HD imaging to initiation of HD was not statistically significant between the CT scan and US groups (Table 1). When compared with non-stone-formers, de novo stone-formers had significantly lower incidence of hypertension (48.2% vs. 14.3%; p=0.03) (Fig. 2, Table 1). There were no significant differences for diabetes, bowel resection, steatohepatitis, gout, sleep apnea, and polycystic kidney disease between stone-formers and non-stone-formers (p>0.05) (Table 1). Dialysis duration was significantly longer in the stone-former group compared with the non-stone-former group (60.5 vs. 59.5 months; p=0.003) (Table 1).

When compared with non-stone-formers, de novo stone-formers had significantly lower serum ionized calcium levels (1.16 vs. 1.07 mmol/L; p=0.01) and magnesium levels (0.95 vs. 0.81 mmol/L; p=0.01), and significantly higher serum uric acid levels (281.5 vs. 319.0 µmol/L; p=0.03) (Table 2). However, no significant differences were observed for the rest of the variables (p>0.05) (Table 2).

On multivariate logistic regression model using Poisson distribution, serum ionized calcium (odds ratio [OR] 0.0001; 95% confidence interval [CI] 0.0–0.18; p=0.01), magnesium (OR 0.0003; 95% CI 0–0.59; p=0.03), and HbA1c levels (OR 0.4845; 95% CI 0.271–0.867; p=0.01) were all independent predictors of stone-formation (Table 3). Dialysis vintage (year of starting dialysis) was not significant factor on the multivariate model (Table 3).

Discussion

The incidence of de novo nephrolithiasis in ESRD patients on HD was found to be 10.5%. This translates to 1.99 patients per 1000 person-months on HD. Therefore, the incidence of de novo nephrolithiasis in ESRD patients on HD is similar to the incidence of nephrolithiasis in the general population of 10.6% in men and 7.1% in women. While not statistically significant, a higher proportion of stone-formers were females (57.1%), opposite to what is typically reported in the non-dialysis population. In addition, these results are congruent with two previous studies demonstrating incidence of de novo nephrolithiasis in patients on chronic HD to be 5–13%. While non-ESRD patients most commonly present with calcium oxalate stones, ESRD patients on chronic HD more commonly form matrix stones. This different stone composition suggests that stone-formation in ESRD HD patients develops via a different mechanism, therefore, different risk factors may be involved in stone-formation in this particular population. Suggested risk factors for matrix stones formation are low urine output, hyperuricemia, β2 microglobulin, high Tamm Horsfall protein content, and duration of dialysis. Other risk factors include recurrent infections, high BMI, proteinuria, and previous history of glomerulonephritis. The median stone density in the present study was 228.5 HU (range 131.5–565.6). Low-density (<500 HU) stones on CT scans may represent uric acid stones or protein-matrix stones, a difference that can only be established through stone analysis. None of the patients in the current study suffered from renal colic and, therefore, they did not require surgical intervention leading to stone extraction and analysis.

Initiation of hemodialysis to de novo nephrolithiasis was 23.5 months. Since loss of urine production (anuria) typically develops within two years post-initiation of HD, it is likely that these stones are being formed while these ESRD patients are still producing urine. In addition, stone-formers were on hemodialysis significantly longer when compared with non-stone-formers (60.5 vs. 59.5 months; p=0.003). Although not clinically significant, one possible explanation is that stone-formers may have started HD earlier while still producing urine. Also, longer dialysis duration is associated with loss of residual renal function and higher β2 microglobulin levels, both of which may be contributing to stone-formation.

Several comorbidities, such as gout or DM, were previously shown to be independent risk factors for stone-formation in the general population. The current study is the first to demonstrate that hypertensive ESRD HD patients formed less stones than their non-hypertensive counterparts. Only 14.3% of stone-formers were hypertensive compared to 48.2% of non-stone-formers patient (p=0.03). A possible rationale may be that the absence of hypertension correlates with the persistence of urine production, which may be a prerequisite for stone-formation. Also, hypertensive patients typically undergo increased ultrafiltration, which may expedite the onset of anuria. As previously noted, the mean time from the start of dialysis to stone-formation (23.5 months) is typically the same period of time associated with the development of anuria in HD patients. In addition, lower magnesium levels in stone-formers may also reflect better residual renal function, as underscored by the persistence of urine output (p=0.01). Although one might have expected lower uric acid levels in patients with better residual renal
function, it is possible that greater urea clearance led to an improved appetite, hence more food-derived uric acid production. The absence of hypertension in stone-former ESRD HD patients differs from the findings of previous studies performed in a non-dialysis population, in whom hypertension and de novo stone-formation were associated. Such a difference between the two populations further suggests that different risk factors for stone-formation exist between the two populations, and conventional risk factors for stone-formation may not apply in ESRD HD patients.

Stone-formers were found to have significantly lower serum ionized calcium levels than non-stone-formers (p=0.01), likely secondary to decreased 1,25(OH)VD levels. Several medications and supplements, such as furosemide and calcitriol supplementation, alter calcium homeostasis and may play a role in stone-formation. However, no significant difference in de novo stone-formation was observed for patients on furosemide or calcitriol supplements (p>0.05). On multivariate regression model using Poisson distribution, ionized calcium levels remained significant (adjusted OR 0.0001; 95% CI 0–0.18). Additionally, stone-formers were found to have significantly lower serum magnesium levels (p=0.01). Magnesium is a known inhibitor of stone-formation, and its decreased levels found in the stone-former population are consistent with prior studies performed on the non-ESRD population. Also, lower serum magnesium has been associated with some degree of parathyroid hormone resistance, which may have further contributed to the lower calcium levels found in stone-formers (p=0.01). On multivariate analysis, magnesium level remained significant (adjusted OR 0.00003; 95% CI 0–0.59), confirming the significance of the univariate analysis. Therefore, lower serum magnesium levels may represent one of the risk factors for nephrolithiasis that is shared between the ESRD HD population and the general population. Finally, although HbA1c levels were not found to be significantly different between the two groups on univariate analysis, the multivariate model showed a significant inverse correlation between HbA1c levels and stone-formation (adjusted OR 0.485; 95% CI 0.271–0.867). Low HbA1c level is a known contributor to frailty status, which in turn is associated with higher inflammatory parameters. Inflammation may be a precursor for stone-formation, as recently shown by the presence of inflammatory cytokines in the papillary tips of stone-formers.

Higher serum uric acid levels are associated with increased stone-formation in a dose-response manner in the general population. In the present study, serum uric acid levels were significantly higher in the stone-formers compared to non-stone-formers (p=0.03). These findings differ from the

| Parameter                           | Overall       | Stone-formers (n=14) | Non-stone-formers (n=56) | p     |
|-------------------------------------|---------------|----------------------|--------------------------|-------|
| Age, median (range) years           | 68.5 (26–89)  | 71.5 (33–84)         | 67 (26–89)               | 0.9   |
| Female, number (percentage)         | 34 (48.6)     | 8 (57.1)             | 26 (37.1)                | 0.4   |
| Weight, median (range) kg           | 81 (50–155)   | 86 (56–128)          | 79 (50–155)              | 0.3   |
| Height, median (range) m            | 1.69 (1.47–1.89) | 1.69 (1.52–1.86) | 1.69 (1.47–1.89)         | 0.6   |
| BMI, median (range) kg/m²           | 28.7 (16–52)  | 30.1 (17.0–51.9)     | 28.2 (16.0–43.4)         | 0.3   |
| Dialysis duration, median (range) months | 59.5 (7–201) | 60.5 (9–121)       | 59.5 (7–201)             | 0.003 |
| Stone density, median (range) HU    | NA            | 260 (141–555)        | NA                       | NA    |
| Largest stone size, median (range) mm | NA         | 4.15 (2.7–12.0)     | NA                       | NA    |
| Time from pre-HD imaging to HD initiation, mean (standard deviation) days | | | | |
| All patients (133)                  | 104 (61)      | NA                   | NA                       | 0.5   |
| CT scan (79)                        | 108 (59)      | NA                   | NA                       | 0.5   |
| US (54)                             | 99 (64)       | NA                   | NA                       | 0.5   |
| Comorbidities (% number)            |               |                      |                          |       |
| Diabetes mellitus                   | 37 (52.9)     | 6 (42.9)             | 31 (55.4)                | 0.4   |
| Hypertension                        | 29 (41.4)     | 2 (14.3)             | 27 (48.2)                | 0.03  |
| Steatorrhea                         | 6 (8.56)      | 2 (14.3)             | 4 (7.1)                  | 0.5   |
| Bowel resection                     | 9 (12.9)      | 3 (21.4)             | 6 (10.7)                 | 0.3   |
| Gout                                | 3 (4.3)       | 1 (7.1)              | 2 (3.6)                  | 0.4   |
| Sleep apnea                         | 13 (18.6)     | 3 (21.4)             | 10 (17.9)                | 0.7   |
| VD deficiency                       | 19 (27.1)     | 2 (14.3)             | 17 (30.4)                | 0.2   |
| Medication (% number)               |               |                      |                          |       |
| Allopurinol                         | 11 (15.7)     | 3 (21.4)             | 8 (14.2)                 | 0.6   |
| Furosemide                          | 17 (24.2)     | 3 (21.4)             | 14 (25.0)                | 1.000 |
| Calcitriol                          | 30 (42.8)     | 5 (35.7)             | 25 (44.6)                | 0.3   |

BMI: body mass index; CT: computed tomography; HD: hemodialysis; NA: not applicable; US: ultrasound; VD: vitamin D.
results of a study by Stankus et al, in which stone-former dialysis patients had similar serum uric acid levels compared to non-stone-formers (6.9 vs. 6.2 mg/L; p>0.05). However, that study relied on patient questionnaires rather than the review of imaging studies that was performed in the present study. In addition, the Stankus et al study included only patients of African-American descent, whereas the current study includes all races. Given that hyperuricemia is an independent risk factor for all-cause mortality in ESRD patients, many patients undergoing dialysis are also prescribed uric acid-lowering medications. Allopurinol is the mainstay for serum and urine urate-lowering therapy. In the current study, no significant difference in de novo stone-formation was observed between patients on and off allopurinol (p>0.05).

Out of the 14 stone-formers, 11 were diagnosed on CT scans and three on US imaging. When reviewing the initial CT reports prior to the review of CT scan images by the two radiologists, only six of 11 reports mentioned renal stones, and two reported vascular calcifications. This underscores the importance of reviewing the CT scans rather than relying on the reports. Out of the 11 patients diagnosed with renal stones on CT scan, nine also had undergone US imaging. Only one of the nine U.S. reports showed the presence of a renal stone. Interestingly, two of nine specifically mention the absence of stones, three mention vascular calcifications, and three do not mention either stone or calcification. Our results are consistent with the results of Fowler et al, who demonstrated decreased sensitivity of US for the diagnosis of renal stones when compared with CT scans. When compared to the general population, dialysis patients have a higher abdominal and subcutaneous fat content, as well as atrophic kidneys, further limiting the sensitivity of US. Additionally, the current study demonstrates that the diagnosis of renal stones in ESRD HD is often missed on CT scans. Possible explanations include renal stones being lower on the differential diagnosis for abdominal or flank pain in this population or stones being mistaken for vascular calcifications in atrophic and highly calcified kidneys.

Our retrospective study includes several inherent limitations. Although recruiting all ESRD patient on HD over a decade from two tertiary care centers, the sample size was relatively small. However, this relatively small sample size was good enough to validate the statistical outcomes using propensity score-matching. Another limitation is the lack of stone analyses and 24-hour urine collections. However, ESRD patients on HD are often oliguric/anuric and urinary collections are often unreliable. In addition, none of the stone-formers had passed the stones for analysis. Finally, dietary restrictions were not controlled for and may have influenced stone composition. However, ESRD patients on HD follow renal diet with fluid restriction. Nevertheless, this was the first study to assess incidence and risk factors for de novo nephrolithiasis in ESRD patients on HD with review of available CT images by two radiologists. The strict inclusion and exclusion criteria, as well as the long follow-up period post-dialysis.

### Table 2. Metabolic workup for stone-formers and non-stone-formers ESRD HD patients after propensity score matching

| Serum variable | n     | Overall (median, range) | Stone-formers (n=14) (median, range) | Non-stone-formers (n=56) (median, range) | p     |
|----------------|-------|-------------------------|--------------------------------------|------------------------------------------|-------|
| Sodium (mmol/L)| 68    | 135 (128–148)           | 135 (128–144)                        | 135 (129–148)                            | 0.7   |
| Potassium (mmol/L)| 68     | 4.6 (2.7–6.5)           | 4.75 (3.3–6.5)                       | 4.5 (2.7–6.5)                            | 0.3   |
| Ionized calcium (mmol/L)| 67   | 1.15 (0.84–1.5)        | 1.07 (0.84–1.25)                    | 1.16 (0.9–1.5)                           | 0.01  |
| Magnesium (mmol/L)| 68    | 0.925 (0.51–1.91)      | 0.81 (0.51–1.03)                    | 0.95 (0.63–1.91)                         | 0.01  |
| Phosphate (mmol/L)| 68    | 1.225 (0.59–4.38)      | 1.23 (0.73–2.1)                     | 1.24 (0.59–4.38)                        | 0.6   |
| Chloride (mmol/L)| 68    | 99 (89–112)            | 100 (89–111)                        | 99 (91–112)                             | 0.5   |
| Bicarbonate (mmol/L)| 68    | 24 (17–32)             | 24 (13–30)                          | 24 (13–32)                              | 0.9   |
| Uric acid (μmol/L)| 68   | 288.5 (119–710)       | 319 (252–483)                       | 281.5 (119–710)                         | 0.03  |
| PTH (pmol/L)| 61      | 30.4 (0.4–167)        | 27.8 (1.1–167)                      | 30.4 (0.4–159)                          | 0.7   |
| Hematocrit   | 57    | 0.312 (0.24–0.5)      | 0.311 (0.25–0.50)                   | 0.32 (0.24–0.4)                         | 0.7   |
| HbA1C (%)   | 44    | 6.05 (4.8–8.7)        | 6.0 (0.12–6.6)                      | 6.1 (4.7–9.7)                           | 0.2   |
| 25(OH)VD (nmol/L)| 40    | 95 (29–185)           | 75 (32–167)                        | 110 (29–185)                            | 0.06  |
| Creatinine (μmol/L)| 70  | 515 (191–1439)        | 515.5 (232–1010)                    | 521.5 (116–1439)                       | 0.9   |

ESRD: end-stage renal disease; HbA1C: glycated hemoglobin; HD: hemodialysis; PTH: parathyroid hormone; 25(OH)VD: 25-hydroxyvitamin D.
(median dialysis duration 59.5 months) constitute strengths of the study. In addition, systematic review of all CT scans was performed by two radiologists using predetermined criteria to identify de novo nephrolithiasis rather than relying on reports of imaging studies or patient questionnaires. Further prospective studies need to include 24-hour urine collections.

### Conclusions

The current study is the first to objectively demonstrate that the incidence of de novo renal stones in the ESRD population is similar to that in the general, healthy population. By reviewing images of CT scans, the incidence of de novo nephrolithiasis in ESRD patients on HD was 10.5%. Increased serum uric acid, decreased serum magnesium and ionized calcium, and absence of hypertension were associated with increased risk of stone-formation in ESRD patients on HD. Future prospective studies including 24-hour urine collections and stone analysis are needed to identify risk factors for stone development in this population.

### Competing interests:
The authors report no competing personal or financial interests related to this work.

### Acknowledgements:
This work was supported in part by the Fond de Recherche en Santé du Québec (FRSQ) Research-Scholar Grant to Dr. Sero Andonian and the Endourological Society Summer Student Scholarship to Charles Hesswani.

This paper has been peer-reviewed.

### References

1. Scales CD, Smith AC, Hanley JA, et al. Prevalence of kidney stones in the United States. *Eur Urol* 2012;62:160-5. https://doi.org/10.1016/j.eururo.2012.03.052
2. Raman V, Akpinar H, Assimos DG. Kidney stones: A global picture of prevalence, incidence, and associated risk factors. *Rev Urol* 2010;12:86-94.
3. Sakhare K, Manodaf NM, Smoot B. Kidney stones 2012: Pathogenesis, diagnosis, and management. *J Clin Endocrinol Metab* 2012;97:1847-60. https://doi.org/10.1210/jc.2011-3492
4. Koulouri O, Jones S, Beable R, et al. Renal calcic in a dialysis patient: A case of renal stone disease. *JRSM Short Reports* 2011;2:57. https://doi.org/10.1258/shorts.2011.011026
5. Viterbo R, Myddel JH. Incidence and management of dialysis patients with renal calculi. *Urológia* 2006;49:306-8. https://doi.org/10.11150/1080-0666
6. Ozessa H, Ote K. Mechanism of kidney stone formation in chronic hemodialysis patients. *Nephron* 1991;58:242-3. https://doi.org/10.1159/000186426
7. Baní-Hernández A, Segura JW, Leroey AJ. Urinary calcium: Our experience at a single institution. *J Urol* 2005;173:120-3. https://doi.org/10.1016/j.juro.2004.12.18824.25
8. Stanikus N, Wentzler E, Hamms K, et al. Evidence against a contribution of conventional urine risk factors to de novo ESRD renal stones. *Nephrol Dial Transplant* 2006;21:701-6. https://doi.org/10.1093/ndt/gfl302
9. Aggarwal S, Tandon C, Farouzandeh M, et al. Role of a protein inhibitor isolated from human renal stone matrix in uretholithiasis. *Indian J Biochem Biophys* 2005;42:119-7.
10. Bendal RB, Ali AA. Comparison of stopping rules in forward regression. *J Am Stat Assoc* 1977;72:46-53. https://doi.org/10.1080/01621459.1977.10479905
11. Parmar MS. Kidney stones. *BMJ* 2004;328:1420-4. https://doi.org/10.1136/bmj.328.7453.1420
12. Bommer J, Ritz E, Tschope W, et al. Urinary matrix calcium consisting of microfibrillar protein in patients on maintenance hemodialysis. *Kidney Int* 1979;16:722-8. https://doi.org/10.1038/kid.1979.188
13. Ozessa H, Suzuki T, Takahashi K, et al. Protein components of amyloid-like kidney stones of chronic hemodialysis patients. *Nephron* 1989;53:257-60. https://doi.org/10.1159/000185754
14. Kippergál KB, Jensen JD, Peters C, et al. Preserving residual renal function in dialysis patients: An update on evidence to assist clinical decision making. *Nephrology Dialysis Transplant* 2011;26:225-30. https://doi.org/10.1093/ndt/gdr235
15. Curhan GC. Epidemiology of stone disease. *Urol Clin N Am* 2007;34:287-93. https://doi.org/10.1016/j.ucl.2006.07.003
16. Gebru D, Bomichais G, Bichardik D, et al. Hypertension in chronic hemodialysis patients: Current view on pathophysiology and treatment. *Clin Nephrol* 2000;53:164-8.
17. Coppucino FP, Blackwood A, Sargnoia GA, et al. Association between extracellular volume expansion and urinary calcium excretion in normal humans. *J Hypertens* 1993;11:519-67. https://doi.org/10.1097/00004872-199312050-00077
18. Hesswani C, Nouréldin YA, Elkousy MA, et al. Combined vitamin D and calcium supplementation in vitamin D inadequate patients with urolithiasis: Impact on hypercalcemia and de novo stone formation. *Can Urol Assoc J* 2015;9:403. https://doi.org/10.5489/cuaj.3332
19. Musc GM. Magnesium metabolism in health and disease. *Int Urol Nephrol* 2009;41:357-62. https://doi.org/10.1007/s11255-009-9548-7
20. Rude RK, Oldham SB, Singer FR. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. *Clin Endocrinol* 1976;5:209-24. https://doi.org/10.1111/j.1365-2265.1976.tb01947.x
21. Yamauchi T, Fujiihara Y, Eda T, et al. Low HbA1c level is associated with severity of frailty in Japanese elderly diabetic patients. *J Diabetes Invest* 2017;9:419-25. https://doi.org/10.1111/jdi.12698
22. Soyal P, Stubbs B, Luoto P, et al. Inflammation and frailty in elderly: A systematic review and meta-analysis. *Ageing Res Rev* 2016;31:1-8. https://doi.org/10.1016/j.arr.2016.08.006
23. Sun Y, Hinck B, Cohen BR, et al. Inflammatory cytokines in the papillary tips and urine of nephrolithiasis patients. *Am J Kidney Dis* 2017;70:2:173-81. https://doi.org/10.1053/j.ajkd.2017.01.053
24. Kim S, Chang Y, Yun KS, et al. Development of nephrolithiasis in asymptomatic hyperuricemia: A cohort study. *Am J Kidney Dis* 2017;70:2:173-81. https://doi.org/10.1053/j.ajkd.2017.01.053
25. Fowler KA, Locken JA, Duchesne JH, et al. US for detecting renal calculi with nonenhanced CT as a reference standard. *Radiology* 2002;222:1:109-13. https://doi.org/10.1148/radiol.2221010453

---

**Correspondence:** Dr. Sero Andonian, Department of Urology, McGill University, Montreal, QC, Canada; sero.andonian@muhc.mcgill.ca